Ana Rita

Nov 7, 2024 | karger.com | Joao Pedro |Ana Cristina |Ana Rita |João Sérgio

Background: Sodium glucose co-transporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists (MRAs) reduce the progression of kidney disease. Whether the combination of these agents provides additional benefits compared to SGLT2i alone is worth exploring using data from randomized trials designed for this purpose. Aims: To assess the randomized treatment effect of MRAs combined with SGLT2i vs SGLT2i alone on markers of kidney and cardiovascular health.

Sep 5, 2024 | link.springer.com | Ana Sofia |Maria Fortuna |de Carvalho |Ana Rita

AbstractThis study aims to review the proposed methodologies and reported performances of automated algorithms for seizure forecast. A systematic review was conducted on studies reported up to May 10, 2024.

Sep 4, 2024 | link.springer.com | Ana Rita |Maria Rosario |Universidade de Coimbra

AbstractAlzheimer’s disease (AD) heritability is estimated to be around 70–80%. Yet, much of it remains to be explained. Studying transmission patterns may help in understanding other factors contributing to the development of AD. In this study, we aimed to search for evidence of autosomal recessive or X- and Y-linked inheritance of risk factors in a large cohort of Portuguese AD patients. We collected family history from patients with AD and cognitively healthy controls over 75 years of age.

Jul 8, 2024 | zenodo.org | Ana Rita

Published July 8, 2024 | Version v1 Dataset Open The genus Distephanus Cass. comprises 43 distinctive species of shrubs and small trees that have been placed historically within the ironweed tribe, Vernonieae (Asteraceae). Utilizing the most expansive sampling of Distephanus to date, this study aims to test the monophyly of this genus and facilitate its classification.

May 20, 2024 | link.springer.com | Ana Rita

AbstractEmpagliflozin is a sodium-glucose co-transporter-2 inhibitor used to treat type 2 diabetes (T2D) to improve glycemic control, reduce risk of cardiovascular death in patients with T2D, and treat patients with symptomatic chronic heart failure (HF) and chronic kidney disease (CKD). The safety profile of empagliflozin is well documented, although adverse events (AEs) remain of interest to clinicians. This study provides an up-to-date safety evaluation of empagliflozin.